In people with both type 2 diabetes and cardiovascular disease, the risk of death from a cardiovascular problem is lowered by: empagliflozin (one of the active drugs in Synjardy) canagliflozin (one of the active drugs in Invokamet) In certain people with type 2 diabetes and kidney damage caused by diabetes, canagliflozin also helps lower the risk of: death from a cardiovascular problem end-stage kidney disease doubled blood level of creatinine (a type of protein) hospitalization from heart failure Drug forms and administration Synjardy and Invokamet both come as tablets that are taken by mouth with food
With the exception of very simple aliphatic acids such as valproic acid (VPA), these molecules conform to a common pharmacophore (Figure 1C), comprising a linker mimicking a lysine side chain, and a cap structure of variable size that makes additional interactions around the rim of the enzyme active site
If achieved, then the broad opportunity emerging from the limited available US experience is to improve real-world outcomes for the many hundreds of thousands of people living with MASH around the world
Abbreviations 5-HIAA: 5-Hydroxyindoleacetic acid 5-HT: Serotonin (5-hydroxytryptamine) BBB: Bloodbrain barrier BDNF: Brain-derived neurotrophic factor cAMP: Cyclic adenosine monophosphate CRH: Corticotropin-releasing hormone CRP: C-reactive protein DPP-4: Dipeptidyl peptidase-4 GABA: Gamma aminobutyric acid GLP-1: Glucagon-like peptide-1 GLP-1R: Glucagon-like-1 peptide receptor GLP-1RA: Glucagon-like-1 peptide receptor agonist HPA: Hypothalamicpituitaryadrenal axis Icv : Intracerebroventricular Ip : Intraperitoneal IL-1: Interleukin-1 beta IL-6: Interleukin-6 NF-B: Nuclear factor kappa-light-chain-enhancer of activated B cells NTS: Nucleus tractus solitarius PKA: Protein kinase A PPG: Preproglucagon PVN: Paraventricular nucleus SCFA: Short chain fatty acid T2DM: Type 2 diabetes mellitus TNF-: Tumor necrosis factor alpha VTA: Ventral tegmental area References Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al
